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Systemic exposure to melphalan is minimized uring isolated limb perfusion (ILP) by isolating a limb from the rest of the 
body. Consequently, there should be no toxicity to vital organs. At present systemic toxicity after ILP has not been studied 
in detail. Therefore, the incidence, nature and risk factors of systemic toxicity was retrospectively studied in 368 patients 
who underwent a single ILP with melphalan between 1978-1990. Some form of systemic toxicity occurred in 98 patients 
(27%). Nausea and vomiting after the 1st post-lLP day was seen in 73 patients (20%), and in seven (2%) treatment was 
required. Bone marrow depression was encountered in seven patients (2"/,,): WHO grade ll in five, and grade III in two. 
Miscellaneous systemic side-effects, including fever and minimal scalp hair loss, occurred in 19 patients (5"/0). Leakage from 
the isolated circuit to the systemic irculation was measured with radioactive tracers. Mean cumulative leakage during ILP 
was 0.9%. Systemic toxicity was not increased in patients with leakage greater than 1% or 5%. Female sex was associated 
with :an increased incidence of systemic toxicity (P<0.05). Age over 60 years (P<0.05) and more severe acute regional 
toxicity (P<0.05) were correlated with nausea and vomiting. The miscellaneous systemic side-effects were more frequently 
encountered in women than in men (P<0.05). In conclusion, systemic toxicity was rarely severe, with nausea and vomiting 
being the most frequently encountered side-effects. Age over 60 years, female sex and more severe acute regional toxic 
reactions were correlated with an increased incidence ofsystemic side-effects. Systemic leakage during ILP was not associated 
with toxicity, probably due to the low incidence of significant leakage. 
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Introduction 
Isolated limb perfusion (ILP) was introduced by Creech et 
al. in 1958. ~ Nowadays, it is an established procedure in the 
treatment of locally inoperable and recurrent melanoma. 2-g 
The main advantage of lLP is that a high dose ofcytostatic 
drug (usually melphalan) can be given loco-regionally, 
thereby minimizing systemic exposure to the drug and 
subsequent toxicity to vital organs. The concentration of 
melphalan in the perfusion circuit is approximately 10times 
higher than the concentration i  blood after maximum- 
tolerated doses normally used for systemic administra- 
tion. 9'~° During ILP, the melphalan peak concentration is
about 150 times higher in the perfusate than in the systemic 
circulation." Therefore, optimal isolation of the limb is of 
utmost importance to avoid leakage of the drug into the 
systemic irculation. Toxicity after systemic administration 
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of malphalan includes bone marrow depression, gastro- 
intestinal toxicity such as nausea and vomiting, diarrhoea 
and stomatitis, hair loss, maculopapular ashes and 
pruritis. ~-' 
Published ata on systemic toxicity after ILP vary widely 
and, given the retrospective nature of most reports, all 
figures probably represent minimum estimates. 3 Mortality 
rates as high as 9% have been reported after ILP, t~ mainly 
from the beginning of the perfusion era. :'j~' ~6 Bone marrow 
depression is encountered in a wide range of 0-59% of 
perfused patients, ~4"~6-4° but data on other potential side- 
effects are scarce. Detailed information on aetiology and 
risk factors for systemic toxicity after ILP with melphalan 
is lacking. A better understanding of the influence of patient- 
and treatment-related factors on systemic toxicity could lead 
to improvements in ILP technology and to the prevention of 
side-effects. 
Moreover, systemic toxicity has become of major concern 
with the recent introduction of tumour necrosis factor-alpha 
(TNFc0 in ILP, 4~ as TNF0t has been associated with severe 
and sometimes life-threatening complications. 4~ 
In this study, we present our experiences with systemic 
toxicity after single ILP with melphalan with respect o 
incidence, nature and risk factors. 
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Table 1. Distribution of patient-and I LP-related variables 
No. of p.'lticnts (%) 
(n = 368) 
Sex 
male 98 (27) 
female 270 (73) 
Age (year) 
<60 229 (62) 
>60 139 (38) 
Level of isolation 
axillary 51 (14) 
brachial 9 (2) 
iliac 257 (70) 
femero-popliteal 51 (14) 
Tissue temperature 
37-38°C 306 (83) 
39 40°C 44 (12) 
41~2°C 18 (5) 
Total dose of melphalan ( ag) 
< 120 306 (83) 
>120 62 (17) 
Leakage to systemic circulation 
_< 1% 298 (81 ) 
>1% 39 ( I I )  
unknown 31 (8) 
Acute regional toxicity 
grade I-I1 309 (84) 
grade I11 V 59 (16) 
Patients and methods 
A total of 499 ILPs in 431 patients with melanoma of 
the limbs were performed in our institutes in the period 
1978-1990. ILPs performed after 1990 were not included in 
this study because of the frequent use of multiple ILP 
schedules and the introduction of TNFa. A computer- 
assisted database, containing all patient, tumour and 
treatment characteristics, allowed the selection of 368 
patients who underwent a single ILP with melphalan. It
cornprised 270 women (73%) and 98 men (27%) with a mean 
age of 52 years (range: 17-83). One-hundred and fifty-eight 
patients (43%) underwent ILP tbr primary melanoma nd 
210 patients (57%) for recurrent melanoma. Patient and 
ILP characteristics are summarized in Table I. 
Our single ILP methodology has been described 
previously in detail. '~:; Isolation of the limb was achieved 
by dissecting and cannulating the main supplying artery 
and vein, and ligating or clamping the main collaterals. For 
the axillary and iliac isolation levels, a Steinmann pin was 
inserted into the head of the humerus or anterior superior 
iliac spine, around which an occluding Esmarch rubber 
bandage was fixed and twisted around the root of the limb, 
proximal to the region of perfusion. This technique prevents 
collateral circulation in muscles, subcutaneous ti sues and 
skin. In 1LPs at the more distal brachial and femoro- 
popliteal isolation levels, an inflating tourniquet was used. 
Fifty-one ILPs (14%) were at the axillary, nine (2%) at the 
brachial, 257 (70%) at the iliac and 51 (14°/.,) at the femoro- 
popliteal isolation 
We essentially focused on the mainte,aance of normal 
physiology in the limb during ILPJ ~ 'Controlled' 
normothermia (tissue temperatures between 37°C and 38°C) 
was routinely applied in 306 ILPs and 'mild' hyperthermia 
(39-40°C) was administered in 44. which were carried out 
in the framework of the prospective randomized WHO/ 
EORTC trial for high-risk stage I melanoma. 4" Eighteen 
patients had been perfused using borderline 'true" 
hyperthermia (41-42°C)J 7Melphalan was routinely given 
in a dose of 10m~l tissues for lower and 13 mg/l for upper 
limb ILPs. 4s''~ Mean melphalan dose given was 91.4rag 
(range: 18.0-165.0 nag). Sixty-two patients (I 7%) received 
more than 120 nag melphalan in the perfusion circuit. The 
priming volume of the extracorporal circuit was 
approximately 750 ml and consisted of whole blood diluted 
with physiological e ectrolyte solutions to a haematocrit of
approxirnately 30. 
The perfusion procedure was flow-regulated. The optimal 
flow rate was considered to be the highest possible flow 
without increasing the venous pressure more than 10cm 
above the starting point and with less than 5% leakage to 
the systemic irculation. A minimal flow rate of 40ml/ 
min/I perfused tissue is generally sufficient, and provides 
physiological blood gas values. The venous pressure in the 
isolated limb was monitored in a peripheral vein at a distal 
site. Any leakage to the systemic irculation was measured 
with a radioactive tracer. A small calibration dose of 
radioactively labelled human serum albunaine (labelled with 
technetium-99m or iodine-131) was given to the systemic 
circulation and a higher dose of the same 
radiopharmaceutical to the isolated limb. Continuous 
monitoring was performed with a precordial scintillation 
probe. Systemic leakage was quantitatively expressed as a 
percentage, whereby a 100% leak was considered to give a 
homogeneous distribution of the tracer in the body:" The 
perfusion duration was 1 h in all ILPs. The mean cumulative 
systemic leakage after 60 rain of I LP was 0.9 + 1.9% (range: 
0-15.6'/,,). Systemic leakage was 1% or less in 298 patients 
(8 I%) and more than 1% in 39 patients (11%). Nine patients 
(3%) had more than 5% leakage during ILP, two of them 
(0.5%) having more than 10%. Leakage was not determined 
in 31 patients (8%), most of whom had ILP at a distal 
isolation level, where systemic leakage is seldorn substantial. 
After the ILP procedure, patients pent one night in the 
Intensive Care Unit. Prophylactic antiemetics were not 
administered. However, most patients required these drugs 
in the first 6-12 h post-lLP. 
Theacute regional toxicity after ILP was graded according 
to Wieberdink et al. (Table 2)J s No, or only slight, skin 
toxicity after ILP (grade I-II) was found in 309 patients 
(84%) and 59 patients (16%) encountered more pronotlnced 
acute regional toxicity (grade Ill-V). The mean hospital 
stay after ILP was 23 days (range: 7-147 days). 
As indicators of systemic toxicity we looked at the 
incidence of nausea nd vomiting, bone marrow depression, 
and miscellaneous side-effects. Nausea/vomiting and bone 
marrow depression as expressed by white blood cell counts 
were graded according to the WHO-criteria (Table 3). -~ In 
70 patients (19°/,,), the number and/or timing of white blood 
cell counts was not sufficient to draw any conclusions 
concerning the presence or absence of bone marrow 
Systemic toXidity @er [LP 
Table 2: Classification of acute regional tissue reactions aceording::to Wieberdink et :aL4S 
:523 
Grade I
Grade II 
Grade HI 
Grade IV 
Grade V 
No subjective or objective vidence of reaction 
Slight erythema, and/or oedema 
con.sidei'ab!e ery~hema and/or 0edema with some iblistering; slightly disturbed motility pgrmissib!e 
Extensive pidermolysis and/or obvious damage to the deep tissues, causing definite functional disturbances; 
fl~reatenihg or manifest compartmental syndromes 
Reaction which may necessitate amputation 
Table 3; Grading of systemlc toxicity after perfusion according to 
WHO~" 
Nausea/vomiting 
grade I nausea 
grade II transient vomiting 
grade HI vomiting requiring therapy 
grade IV intractabie: vomitigg 
Bone marrow depression 
grade I WBC 3i0-3i9 !09/I 
grade 1! WBC 2:0--2.9 109/I 
grade III wBC 1,0-1;9 109/1 
grade !V WBC <1,0 109/1 
WBC White bl0od cell count. 
depressiom Leucocyte counts of less than 3.0x 109/l were 
considered indicators of~ignificant bone marrow depression 
(WHO grade [I-HI). Nausea and/or vomiting was 
considered as showing-significant systemic toxicity when it 
occurred (or was sti,ll presem) more than 24h after ILR 
The following patient- and treatment-related factors were 
tested using the chi-square method for their influence on 
systemic side-effects: ex, age (<60 vs > 60 years), total dose 
of melphalan (_< 120 vs >120mg), systemic leakage (_~ 1 vs 
>1% and <5 vs >5%) and acute regionaL toxicity (grade 
I- I I  vs, III-V). 
Results 
There was no post-operative mortality in the selected 368 
patients. Some form of systemic toxicity during hospital 
stay occurred in 98 patients (27%), inclUding nausea/ 
vomiting after the first post-operative day in 73 patients 
(20% of the 368 patients), which required the administration 
of antiemetics (domperidon, metocloprmnide, droperidol) 
in seven patients (2%) (Fig. 1). Bone marrow depression 
was encountered in 32 patients (9%): grade I in 25 (7°,4)~ 
grade II in five (1.5%) and grade III in two patients (0.5%) 
(Fig. 2). The white blood cell counts reached t~heir nadir 
after a median period of 6 days in patients with grade I, 
and 1.4 days in patients with grade II-and III bone marrow 
depression. Bone marrow depression was transient in all 
cases. Other~systemic s de:effects, uch as fever and minor 
scalp hair loss, occurred in 19 patients (5°,4) and are listed 
m Table 4. 
Table 5 shows the patient- and peffusion~related~variables 
tested (z2-test) as possible risk factors:.for systemic toxicity. 
Sex appeared to :be a significant factor associated with 
systemic toNcity (P<0.05), with women having a higher 
probability of de~eloping systemic side-effects. Systemic 
toxicity also.seemed to be.somewhat higher in: patients who 
grade:Ill 2% 
a0~ grade I 
none 80% 
Fig. 1. Nausea and vomiting after ILP with melphalart. 
none 72.0% 
co-  :-'~- E 
/ :  ~ u n k n o w n  19.0% 
- -  , !iiiiiiifiiiTiiii!ii   
~ grade I 7 0% 
• / 
Fig. 2. Bone marrow depression after ILP with melphalan. 
Table 4. Distribution of miscel aneous ystemic side,effects (N= 19) 
Side-effect n (%) 
Fever 10 (2.7%) 
Minimal scalp hair loss 2 (0.5%) 
Mild biochemical hepatotoxicity 2 (0~5%) 
Reversible renal failure not necessitating dialysi~s 2 (0.5%) 
Other (supraventficular t ehycardia, myocardial 
inl'arction, gastric bleeding) 3 (0.8%) 
received more :than 120rag melphalan in the perfusion 
circuit (P=0d,0)+ 
All variables were also tested for Ztheir influence on the 
different forms .of systeraie' toxicity .(Table 5). :Age over 60 
years (ao<0.05) and more sevel"e acute regional toxicity 
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(P<0.05) were both correlated with post-operative nausea 
and vomiting. Bone marrow depression seemed to occur 
more frequently in patients who received more than 120 mg 
melphalan (P<0.10) and these patients tended also to have 
more severe limb toxicity (P<0.10). The miscellaneous 
systemic side-effects occurred significantly more frequently 
in women than in men (P<0.05). 
No correlation was found between the occurrence of 
systemic toxicity and leakage greater than 1%. Also none 
of the separate forms of systemic toxicity was associated 
with leakage. Also leakage of 5% or more could not predict 
systemic side-effects. In the two patients with grade III bone 
marrow depression, systemic leakage was less than I%. 
None of the seven patients with vomiting requiring therapy 
had a systemic leak greater than I%. High systemic leakage 
(more than 10%) was found in only two patients (15.0 
and 15.6%, respectively). Neither developed bone marro,/v 
depression but the latter appeared to have nausea nd fever 
post-operatively. 
Discussion 
Mortality during the post-operative p riod was not seen in 
present series of 368 patients. In the iiterature, mortality 
rates after ILP with melphalan range from 0-9"/,, ~~ (Table 
6)j4.~6 4o with deaths mainly occurring in the early years of 
ILP experience._,.~4 ~6 Mortality usually results from 
pulmonary emboli, cardiac failure, renal failure, or bone 
marrow depression? 4'~t' 1825.32.35 7 
The incidence of severe systemic toxicity after a single 
'ILP with melphalan was minimal in the present series. 
Leucopenia (white blood cell counts <l .0x  109/I, WHO 
grade IV toxicity) was not encountered. Only two patients 
(0.5%) developed transient grade III bone marrow 
depression. Most patients had nausea and/or vomiting 
during the first 6-12 h tbllowing ILP. Intractable vomiting 
was not seen post-operatively, 2% of the patients required 
conventional antiemetic treatment after the first post- 
operative day with satisfactory results. Marked stomatitis, 
diarrhoea, maculopapular rashes and pruritis, commonly 
observed after the systemic administration of melphalanJ-' 
were not seen. Minimal scalp hair loss was seen in only two 
patients (0.5%), but without a striking aesthetic effect. 
The absence of severe systemic toxicity can be explained 
by the low percentage of leakage to the systemic irculation 
during ILP in our series. 5-' Leakage of cytostatic drug has 
been associated with the occurrence of systemic side- 
effects. 5"-'6'33'u''~8 It is known from literature data that total 
leakage values during ILP up to 15% do not cause severe 
systemic toxicity. 53 When melphalan isgiven in a single dose 
at the start of ILP, as in our series, the concentration of 
melphalan in the perfusate declines rapidly during the early 
phase of drug circulation; there is a 40-50% decrease after 
10min of ILP and after 30min almost all melphalan has 
accumulated in the tissues. ~'~°'s4 Therefore, it is not surprising 
that melphalan toxicity to the bone marrow was clearly 
related to greater leakages during the first 5-10min of 
ILP in other studies. -'6'3s Hence, melphalan should not be 
administered until haemodynamics have stabilized, and 
there should be no leakage of the perfusate into the systemic 
circulation. 
On the other hand, systemic toxicity occurred to some 
extent in about one-quarter of perfused patients. In most 
cases this was gastro-intestinal toxicity with nausea, retching 
and transient vomiting which usually started in the 
immediate post-operative p riod lasting lbr more than 24 h. 
We feel that nausea nd vomiting is more pronounced after 
ILP compared with other surgery of the same duration and 
extent. These symptoms can be particularly distressing alter 
ILP at the iliac level (which requires a sizeable incision 
through the musculature of the iliac fossa) because they 
cause a great deal of additional pain) 5 Patients older than 
60 years were significantly more frequently affected by this 
complication than younger patients in our series. However, 
these side-effects cannot be attributed completely to the 
melphalan alone as vomiting has also been reported in 
10-50% of patients following routine surgery with general 
anaesthesia. 56 Besides, melphalan leakage during ILP was 
not associated with prolonged post-operative nausea and 
vomiting in the present study. Maybe the combination of 
melphalan, anaesthetic agents, major surgery and post- 
operative narcotic analgesics given to control pain, is a 
powerful emetogenic stimulus, t~'Ss Pain itself and the release 
of waste products from the perfused limb may also be 
involved, as in our series more severe limb toxicity was 
associated with nausea and vomiting. 
The recently developed serotonin antagonists provide 
excellent antiemetic control in patients treated with systemic 
chemotherapy or following surgery. 57 6~ A single 8 mg dose 
of ondansetron (Zofren ®) given intravenously at the time 
of anaesthetic nduction has been reported to be effective 
in controlling nausea and vomiting in the great majority 
of patients after ILP. s5 As most of our patients required 
antiemetic therapy in the first hours post-operatively, it 
seems better to anticipate vomiting by the prophylactic 
administration of these drugs. 
Due to differences in what investigators are willing to list 
as significant bone marrow depression following ILP, it is 
difficult to compare our results with those of others. In 9% 
of our patients white blood cell counts passed the lower 
limit of normal during hospital stay (4.0 x 109/I). However, 
for patients with grade I bone marrow depression the timing 
of the maximum fall suggested that it was related to fluid 
shifts rather than a drug effect. 6-''63 The incidence of 
significant bone marrow depression (as expressed by white 
blood cell counts lower than 3.0 x 10'~/1) in our series (2%) 
is low-compared with literature data, where bone marrow 
depression is reported in up to 59% of perfused patients 
(Table 6). t~''~° 
As systemic leakage during ILP was not significantly 
associated with bone marrow depression, a phenomenon 
reported before, s't9 other factors may have played a role in 
our series, such as the total dose of melphalan. This link 
between total drug dose and enhanced bone marrow 
depression has also been noticed by other investigators. "3'64 
Despite very careful wash-out procedures, systemic peak 
concentrations of melphalan have been observed after 
reconnection of the perfused limb to the systemic 
circulation. 4°'5'- Systemic drug levels after ILP may derive 
from the intravascular components of the limb H'4°'5-" or via 
Systemic toxici O, a['ter ILP 
"Fable 5. Risk factors for systemic toxicity after ILP with melphalan 
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Systemic toxicity N/V* BMDt Miscellaneous 
Sex 
(~3 vs 9) P<0.05 NS NS P<0.05 
Age (years) 
(<60 vs >60) NS P<0.05 NS NS 
Total dose (rag) 
(_< 120 vs >120) P=0.10 NS P<0.10 NS 
Leakage (%) 
(< vs >1) NS NS NS NS 
Regional toxicity 
[grade I-l l  vs Il l-V) NS P<0.05 P<0.10 NS 
*Nausea and vomiting grade 1-111 according to WHO criteria. 
tBone marrow depression grade 11-III according to WHO criteria. 
NS = not significant. 
release o f  the t i sshe-bound rug?  Therefore,  the total dose 
o f  me lpha lan  employed may be related to the amount  
enter ing the systemic circulat ion after ILP and so may be 
responsib le for systemic toxicity. 
In 3% of  our  pat ients fever (38-40°(2) was noted in the 
immedia te  post -operat ive period wi thout  any evidence o f  
infection. Fever has been reported to occur  in up to 42% 
of  pat ients tbl lowing ILP  with melpha lan.  "~ It could be a 
result o f  the surgical t rauma itself, the in f lammatory  state 
o f  the perfused l imb, '~' necrosis  of  muscle,  ~'7 or induct ion o f  
host -mediators .  6~ Treatment  is usual ly not  required after 
exclusion o f  possible infectious aetiologies. 
The  reason why women had an increased risk on systemic 
side-effects is not  unders tood  and can only be speculated.  
Our  rather long mean hospital  stay o f  approx imate ly  3 
weeks included a rout ine 3 day pre-operat ive work -up  period 
Table 6. Systemic toxicity after ILP with melphalan: review of the literature 
Author Period A t* BM D("/,,) SHL(%) Mortality("/,,) 
Stehlin 17"Is 1958-1964 221 1.8 - -  0.5 
1967-1974 185 - -  - -  1.1 
Irvine ~' 1966t 29 31 - -  0 
Shingleton:" 1961 1968 35 14 0 
McBride 16 1958-1969 678 1.2 - -  0.7 
Fontaine '~ 1974t 56 5 - -  0 
Golomb-'-' 1959-1976 114 23 - -  0 
Hansson -'3 1966-1974 22 32 9 0 
J6nsson 'a 1976-1981 80 0 - -  0 
Lejeune -'s'-'~ 1983"I" 23 26 - -  9 
1989t 206 I - -  1 
Rege -'v 1962-1979 39 0 - -  3 
Minor 2~ 1985t 28 7 - -  0 
Fletcher -''~ 1965-1983 23 4.3 - -  0 
Krementz ~4 1957-1966 317 12.2 3.8 2.5 
1967-1974 278 4.0 0.7 0.4 
1975-1982 275 3.6 0 0 
Vaglini u~ 1982-1985 95 5 - -  0 
Krige ~ 1976-1982 93 3 - -  0 
Di Filippo 3-" 1969-1986 136 35 - -  5.9 
Santinami 3~ 1981-1987 140 3.5 - -  0 
Kettelhack ~ 1982-1989 113 1.8 - -  0 
Pace 3~ 1990t II 1 18 3.6 0.9 
Skene 3~ 1979-1987 91 7 - -  2 
Hafstr6m ~7 1981-1989 33 3 - -  3 
Neades u 1985-1989 26 31 8 0 
Omlor ~ 1989-1991 36 - -  6 0 
Rauschecker ~ 1990t 44 59 - -  - -  
*Number of ILPs (if not known: number 
BMD: bone marrow depression. 
SHL: scalp hair loss. 
t Year of publication. 
of patients). 
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and reflects merely the duration of the acute regional toxic 
reactions in the perfused limb. During the study period, 
patients were only discharged when fully mobilized. 
In contrast with the negligible incidence of severe systemic 
side-effects after modern ILP with melphalan, the 
complications associated with the recently introduced 
biological response modifier TNF~t in ILPcan be impressive. 
Application of high doses of TNF~, in contrast to 
melphalan, maintains high stable drug levels in the perfusate 
throughout the ILP, 4~ and can lead to prolonged high 
systemic levels and induce a systemic inflammatory response 
syndrome comprising feve," and chills, hypotension and 
ARDS?~ 44.,,:, This toxicity is directly correlated to leakage 
during ILP and can be almost completely prevented by 
adequate leakage control and extensive washout procedures 
at the end of the ILP. 4L7~ It is also our experience that when 
leakage is abolished and tborough washout is performed~ 
only a short-lived (less than 1 h) systemically measurable 
TNFT-peak is observed and systemic toxicity is restricted 
to the induction of fever and limited to the day of ILP. 7-" 
In conclusion, systemic toxicity occurred in one-quarter 
of our patients after 1LP with melphahm but was rarely 
severe, probably as a result of the low systemic leakage 
percentage. Nausea and vomiting were the most frequently 
encountered side-effects. Age over 60 years, female sex and 
more severe limb toxicity proved to be factors associated 
with an increased incidence of systemic side-effects, drug 
leakage during I LP was not. These prognostic factors should 
be considered in attempts to decrease systemic toxicity after 
ILP. 
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